ClinicalTrials.gg
RecruitingNCT05459519FUTUREUpdated Jul 25, 2023

Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease

An interventional study of Dengzhanxixin Capsule plus Placebo Capsule and Placebo in Diabetes, Hypertension and Hypercholesterolemia, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.

Planned enrollment
127th of 280
165 · median 143
Started
2022
with 35 others
No phase
118 of 417
27 open now
Primary completion
2023-12
later than 3 of 116 live
Registered
259th of 417
by date

Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 127th largest by planned enrollment of the 280 interventional ones that give a count, is one of 36 that started in 2022, is one of 118 with no phase, reaches primary completion later than 3 of the 116 other live ones, and was the 259th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Diabetes Mellitus with a site in China, or all of them as a file.
02

Study summary

The main objective of this clinical trial is to evaluate whether the antiplatelet efficacy of the Dengzhanxixin capsule is better than that of placebo in individuals at high-risk for atherosclerotic cardiovascular disease (ASCVD).

Read the detailed description

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of cardiovascular death, and one out of every ten people aged 35-75 in China is at high risk for ASCVD. Platelet activation is an important mechanism for the development of atherosclerosis. Antiplatelet therapy is important in preventing ASCVD.

Dengzhanxixin capsule is an over-the-counter Chinese traditional medicine; currently, it is mainly used for the adjuvant treatment of ischemic stroke and coronary heart disease. A study of 3143 patients with ischemic stroke found that the addition of Dengzhanshengmai capsules to the standard treatment could further reduce the risk of recurrent stroke and was well tolerated without increased risk of bleeding. Animal experiments also observed that Dengzhanxixin capsules had a clear antiplatelet effect. However, the antiplatelet function of Dengzhanxixin capsules in humans is still unclear. In addition, Dengzhanxixin capsules also have potential anti-inflammatory, lipid-lowering, anticoagulant, and antihypertensive effects.

The main objective of this study is to evaluate the antiplatelet efficacy and safety of Dengzhanxixin capsules in individuals at high-risk for ASCVD. The plan of the study is to recruit 165 subjects and the follow up is to be 10 weeks. This study has been approved by the Ethics Committee of Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen.

03

Conditions studied

  • Diabetes
  • Hypertension
  • Hypercholesterolemia

Keywords

  • dengzhanxixin capsule; platelet function; primary prevention
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following three conditions must be met at the same time:

  1. Age > 40 years, \< 70 years
  2. Meet any of the following conditions:

    i) Diabetes

    ii) LDL-C ≥ 4.9 mmol/L or TC ≥ 7.2 mmol/L

    iii) Hypertension; 1.8 mmol/L ≤ LDL-C \< 2.6 mmol/L or 3.1 mmol/L ≤ TC \< 4.1 mmol/L; 3 risk factors (including smoking, HDL-C \< 1.0 mmol/L, ≥ 45 years for male or ≥ 55 years for female)

    iv) Hypertension; 2.6mmol/L ≤ LDL-C \< 4.9mmol/L or 4.1mmol/L ≤ TC \< 7.2mmol/L; with 2 or more risk factors (same risk factors as above)

  3. Sign the

Exclusion criteria

Exclusion Criteria:

Those who meet any of the following conditions are not eligible:

  1. Diagnosed ASCVD, such as coronary heart disease, stroke and peripheral vascular disease
  2. Past history of heart failure
  3. History of symptomatic non-traumatic intracerebral hemorrhage at any time
  4. History of gastrointestinal bleeding within the past 3 months or history of major surgery within 30 days
  5. Need to use anticoagulation, antiplatelet or frequent use of non-steroidal anti-inflammatory drugs
  6. Have used Dengzhanxixin or preparations containing Dengzhanxixin in the past 1 month
  7. Have clear adverse reactions to Dengzhanxixin in the past
  8. Active liver disease, or (ALT) or aspartate aminotransferase (AST) levels > 2 times the (ULN)
  9. Chronic kidney disease, or estimated (eGFR) \<60ml/(min×1.73m2)
  10. Pregnant or planning to become pregnant, or breastfeeding
  11. Malignant tumors, or other serious diseases with an expected survival period of less than 1 year
  12. Mental disorders or communication disorders, cognitive dysfunction, or other serious diseases that may affect participation in the study
  13. Have participated in or are participating in other clinical trials in the past 1 month
  14. Known poor adherence to study follow-up or study medication
  15. Acute stage of disease: acute fever, acute pancreatitis, etc.

In addition, subjects will be excluded from the randomization clinic if they have any of the following situations:

  1. Failure to complete the lead-in treatment
  2. The occurrence of placebo-related adverse reactions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Intervention group A

    Dengzhanxixin Capsules plus Placebo Capsules

    Drug: Dengzhanxixin Capsule plus Placebo Capsule

  • Experimental
    Intervention group B

    Dengzhanxixin Capsules plus Placebo Capsules

    Drug: Dengzhanxixin Capsule plus Placebo Capsule

  • Placebo comparator
    Control group

    Placebo Capsules

    Drug: Placebo

Interventions

  • DrugDengzhanxixin Capsule plus Placebo Capsule

    Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily

  • DrugPlacebo

    Placebo, 4 capsules each time, twice daily

  • DrugDengzhanxixin Capsule plus Placebo Capsule

    Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily

06

What researchers measure

Primary outcomes

  1. Changes in rate of platelet aggregation

    inhibition of adenosine diphosphate (ADP)-induced platelet aggregation as measured by optical aggregometry at week 8.

    Time frame: "Day 0", "Week 8"

Secondary outcomes

  1. Changes in rate of platelet aggregation

    1. inhibition of arachidonic acid (AA) and collagen (COLL) -induced platelet aggregation measured by optical aggregometry at week 8. 2. inhibition of ADP, AA and COLL -induced platelet aggregation measured by optical aggregometry at week 4. 3. At 4 weeks and 8 weeks from baseline, compare the differences of platelet P2Y12 response units (PRU) and aspirin response units (ARU) 4. At 4 weeks and 8 weeks of treatment, compare the differences of P-selectin.

    Time frame: "Day 0","Week 4","Week 8"

  2. Changes in blood pressure

    Changes in systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  3. Changes in serum lipid profile

    changes in total cholesterol (mg/dL) , low-density lipoprotein cholesterol ester (mg/dL) , high-density lipoprotein cholesterol ester (mg/dL) , triglyceride (mg/dL) and lipoprotein(a) (mg/dL) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  4. Changes in coagulation profile

    changes in prothrombin time (s), activated partial thromboplastin time (s), and thrombin time (s) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  5. Changes in fibrinogen

    changes in fibrinogen (g/L) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  6. Changes in hs-CRP

    changes in high-sensitivity C-reactive protein (mg/dL) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  7. Changes in IL-6

    changes in interleukin-6 (pg/mL) at 4 and 8 weeks of treatment compared with baseline

    Time frame: "Day 0","Week 4","Week 8"

  8. Changes in HbA1c(%)

    Changes in HbA1c at 8 weeks of treatment compared with baseline

    Time frame: "Day 0", "Week 8"

  9. Number of Participants with safety endpoint

    2) Liver-relate indicators: 1. ALT ≥ 5 times ULN, or 2. ALT ≥ 3 times ULN + bilirubin ≥ 2 times ULN (3) Kidney-related indicators: a. Serum creatinine increased by ≥50% from baseline, or b. Change in eGFR from baseline (4) Serious adverse events (5) Other adverse events related to the study drug (6) Drug discontinuation due to any reason

    Time frame: through study completion, an average of 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2022
First posted
Jul 15, 2022
StartActual
Jul 20, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05459519
Collaborators
Fuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, Shenzhen
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Jul 20, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jul 25, 2023

Study contacts

Xin Zheng, Ph.D
Contact
xin.zheng@fwoxford.org
Xiaofang Yan, M.S
Contact
xiaofang.yan@fwoxford.org
Xin Zheng, Ph.D
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital
Jing Li, Ph.D
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion